Nifty
:
23618.00
Sensex
:
75200.85
-31.95 (-0.14%)
-114.19 (-0.15%)
Nifty
Sensex
:
:
23618.00
75200.85
-31.95 (-0.14%)
-114.19 (-0.15%)

Zim Laboratories Ltd.

Pharmaceuticals & Drugs

Rating :
54/99

BSE: 541400 | NSE: ZIMLAB

NSE BSE
100.60
19-May-2026
  • Open
  • High
  • Low
  • Previous Close
  •  97.9
  •  102.28
  •  93.2
  •  97.41
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  45544
  •  4542819.92
  •  127
  •  59.31

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 539.77
  • 92.46
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 619.35
  • N/A
  • 1.86

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 30.35%
  • 17.06%
  • 32.77%
  • FII
  • DII
  • Others
  • 0%
  • 0.00%
  • 19.82%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.51
  • 4.29
  • -1.66

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.12
  • 1.92
  • -3.40

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.08
  • 10.68
  • -20.75

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 28.17
  • 30.44
  • 31.58

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.67
  • 1.95
  • 2.08

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.17
  • 10.46
  • 11.79

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Net Sales
105.27
108.73
-3.18%
108.66
96.33
12.80%
88.71
92.14
-3.72%
71.76
81.82
-12.30%
Expenses
98.08
94.14
4.19%
95.85
84.77
13.07%
82.96
82.61
0.42%
67.50
73.79
-8.52%
EBITDA
7.19
14.60
-50.75%
12.80
11.56
10.73%
5.75
9.53
-39.66%
4.26
8.04
-47.01%
EBIDTM
6.83%
13.42%
11.78%
12.00%
6.49%
10.34%
5.94%
9.82%
Other Income
6.16
1.71
260.23%
1.70
1.76
-3.41%
2.04
1.32
54.55%
1.48
1.00
48.00%
Interest
3.31
2.91
13.75%
3.43
2.73
25.64%
3.16
2.89
9.34%
3.30
2.86
15.38%
Depreciation
5.10
5.29
-3.59%
5.03
4.88
3.07%
4.98
5.00
-0.40%
4.86
4.94
-1.62%
PBT
4.94
8.11
-39.09%
6.05
5.70
6.14%
-0.34
2.96
-
-2.43
1.23
-
Tax
1.20
3.22
-62.73%
1.65
1.70
-2.94%
0.08
0.58
-86.21%
-0.56
0.34
-
PAT
3.74
4.88
-23.36%
4.40
4.00
10.00%
-0.42
2.38
-
-1.88
0.90
-
PATM
3.55%
4.49%
4.05%
4.15%
-0.48%
2.58%
-2.61%
1.10%
EPS
0.70
1.00
-30.00%
0.90
0.82
9.76%
-0.09
0.49
-
-0.38
0.18
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
374.40
379.03
367.42
398.53
333.43
307.26
277.74
335.37
272.80
235.01
268.51
Net Sales Growth
-1.22%
3.16%
-7.81%
19.52%
8.52%
10.63%
-17.18%
22.94%
16.08%
-12.48%
 
Cost Of Goods Sold
165.38
167.85
171.44
198.83
160.35
158.63
143.14
159.51
140.89
119.96
157.72
Gross Profit
209.02
211.18
195.98
199.69
173.08
148.63
134.60
175.86
131.91
115.04
110.79
GP Margin
55.83%
55.72%
53.34%
50.11%
51.91%
48.37%
48.46%
52.44%
48.35%
48.95%
41.26%
Total Expenditure
344.39
335.30
326.09
346.54
292.45
267.50
255.13
293.34
238.02
203.53
239.32
Power & Fuel Cost
-
17.39
13.47
11.09
9.14
7.04
7.47
7.19
5.75
5.35
6.40
% Of Sales
-
4.59%
3.67%
2.78%
2.74%
2.29%
2.69%
2.14%
2.11%
2.28%
2.38%
Employee Cost
-
60.76
53.34
49.32
40.07
35.76
35.35
48.26
40.80
33.00
30.70
% Of Sales
-
16.03%
14.52%
12.38%
12.02%
11.64%
12.73%
14.39%
14.96%
14.04%
11.43%
Manufacturing Exp.
-
38.37
39.34
33.83
29.03
23.40
26.97
13.62
7.82
7.76
7.25
% Of Sales
-
10.12%
10.71%
8.49%
8.71%
7.62%
9.71%
4.06%
2.87%
3.30%
2.70%
General & Admin Exp.
-
20.21
17.98
19.55
15.82
10.72
11.61
14.53
10.85
10.30
8.61
% Of Sales
-
5.33%
4.89%
4.91%
4.74%
3.49%
4.18%
4.33%
3.98%
4.38%
3.21%
Selling & Distn. Exp.
-
24.12
24.48
27.94
32.70
27.96
24.51
45.61
28.22
22.53
22.04
% Of Sales
-
6.36%
6.66%
7.01%
9.81%
9.10%
8.82%
13.60%
10.34%
9.59%
8.21%
Miscellaneous Exp.
-
6.61
6.04
5.98
5.35
3.98
6.07
4.62
3.69
4.62
22.04
% Of Sales
-
1.74%
1.64%
1.50%
1.60%
1.30%
2.19%
1.38%
1.35%
1.97%
2.46%
EBITDA
30.00
43.73
41.33
51.99
40.98
39.76
22.61
42.03
34.78
31.48
29.19
EBITDA Margin
8.01%
11.54%
11.25%
13.05%
12.29%
12.94%
8.14%
12.53%
12.75%
13.40%
10.87%
Other Income
11.38
5.78
5.18
6.41
4.40
2.34
4.52
2.05
3.42
5.51
3.91
Interest
13.20
11.39
6.92
5.58
8.31
10.90
12.65
10.59
9.34
10.47
13.65
Depreciation
19.97
20.11
15.95
17.47
16.03
15.79
14.41
11.42
9.79
9.02
8.76
PBT
8.22
18.01
23.64
35.35
21.04
15.41
0.07
22.07
19.07
17.50
10.69
Tax
2.37
5.84
6.40
10.92
6.49
2.91
-3.23
6.73
5.83
-1.09
0.26
Tax Rate
28.83%
32.43%
27.07%
30.89%
30.85%
28.45%
-4614.29%
30.49%
23.39%
-6.23%
4.85%
PAT
5.84
12.16
17.25
24.43
14.55
7.32
3.30
15.34
19.11
18.59
5.10
PAT before Minority Interest
5.84
12.16
17.25
24.43
14.55
7.32
3.30
15.34
19.11
18.59
5.10
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
1.56%
3.21%
4.69%
6.13%
4.36%
2.38%
1.19%
4.57%
7.01%
7.91%
1.90%
PAT Growth
-51.97%
-29.51%
-29.39%
67.90%
98.77%
121.82%
-78.49%
-19.73%
2.80%
264.51%
 
EPS
1.09
2.27
3.22
4.57
2.72
1.37
0.62
2.87
3.57
3.47
0.95

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
252.24
238.75
200.35
175.71
160.75
153.82
151.12
136.60
118.33
98.96
Share Capital
48.73
48.73
48.73
16.24
16.24
16.18
16.12
8.06
8.03
8.00
Total Reserves
202.16
190.02
151.62
159.47
144.51
137.28
133.77
127.95
109.59
90.34
Non-Current Liabilities
53.42
48.65
30.45
20.01
19.40
22.72
20.19
16.61
18.09
34.75
Secured Loans
40.30
35.60
24.62
18.92
21.83
27.01
19.14
15.91
26.75
33.98
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.41
3.02
4.37
0.77
0.77
Long Term Provisions
0.00
0.00
0.00
0.00
0.01
0.00
0.10
0.00
0.00
0.00
Current Liabilities
166.36
159.43
110.79
147.37
142.04
143.44
156.40
141.40
113.21
123.65
Trade Payables
69.51
62.38
58.24
81.07
64.87
66.00
71.95
66.26
45.05
46.97
Other Current Liabilities
40.80
41.21
29.07
44.71
31.16
26.68
38.65
25.15
18.33
16.71
Short Term Borrowings
52.46
55.04
22.88
17.34
44.60
49.69
40.15
49.56
46.70
56.30
Short Term Provisions
3.60
0.80
0.59
4.24
1.40
1.06
5.65
0.43
3.14
3.68
Total Liabilities
472.02
446.83
341.59
343.09
322.19
319.98
327.71
294.61
249.63
257.36
Net Block
164.28
160.83
108.66
105.64
106.52
115.92
106.01
94.16
88.75
92.19
Gross Block
274.88
266.57
198.66
180.24
165.49
159.23
135.67
112.90
97.77
120.36
Accumulated Depreciation
110.61
105.74
90.01
74.60
58.97
43.31
29.66
18.74
9.02
28.17
Non Current Assets
240.72
219.17
150.63
129.49
130.43
137.94
132.39
121.68
95.86
102.02
Capital Work in Progress
70.46
42.28
26.99
11.74
10.68
9.62
13.32
8.29
3.82
2.93
Non Current Investment
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
Long Term Loans & Adv.
5.16
15.71
14.41
11.78
11.32
10.40
11.72
18.05
3.07
6.36
Other Non Current Assets
0.76
0.31
0.52
0.28
1.85
1.95
1.29
1.13
0.16
0.48
Current Assets
231.31
227.65
190.95
213.59
191.76
182.03
195.32
172.94
153.77
155.34
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
86.47
81.26
53.71
75.28
54.35
56.39
55.05
51.56
35.47
37.72
Sundry Debtors
106.92
100.17
95.25
89.52
72.25
67.93
93.10
89.22
88.18
88.53
Cash & Bank
2.49
10.46
7.52
4.97
8.35
3.95
2.94
3.53
5.61
6.39
Other Current Assets
35.43
2.29
2.56
1.41
56.81
53.76
44.23
28.63
24.52
22.70
Short Term Loans & Adv.
32.33
33.46
31.91
42.41
55.26
52.16
42.83
27.51
23.51
21.49
Net Current Assets
64.94
68.22
80.16
66.23
49.72
38.60
38.92
31.54
40.56
31.69
Total Assets
472.03
446.82
341.58
343.08
322.19
319.97
327.71
294.62
249.63
257.36

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
41.15
16.28
38.17
49.21
31.85
21.92
34.94
36.68
32.07
21.94
PBT
18.01
23.64
35.35
21.04
15.41
0.07
22.07
24.94
17.50
5.36
Adjustment
32.43
22.01
22.16
22.01
25.79
26.25
23.82
12.84
20.78
29.04
Changes in Working Capital
-10.36
-26.79
-12.19
6.58
-8.24
0.56
-9.64
2.96
-3.72
-11.32
Cash after chg. in Working capital
40.08
18.86
45.32
49.64
32.96
26.87
36.25
40.73
34.56
23.08
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
1.08
-2.58
-7.15
-0.43
-1.11
-4.96
-1.31
-4.06
-2.49
-1.14
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-39.93
-73.01
-36.20
-14.57
-5.88
-19.41
-20.68
-25.83
-7.24
-11.73
Net Fixed Assets
-33.16
-81.96
-32.76
-15.55
-7.23
-19.28
-22.29
-19.60
21.70
Net Investments
-4.81
-0.05
0.00
-0.10
0.00
-3.54
-4.45
0.00
0.00
Others
-1.96
9.00
-3.44
1.08
1.35
3.41
6.06
-6.23
-28.94
Cash from Financing Activity
-9.10
59.53
0.55
-32.97
-25.97
-2.16
-15.16
-9.80
-25.15
-10.35
Net Cash Inflow / Outflow
-7.88
2.80
2.51
1.66
0.00
0.35
-0.90
1.04
-0.32
-0.14
Opening Cash & Equivalents
9.60
6.42
3.42
1.39
1.46
0.50
1.47
0.42
0.74
0.88
Closing Cash & Equivalent
1.95
9.60
6.42
3.42
1.39
1.46
0.50
1.47
0.42
0.74

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
51.49
49.00
41.12
36.06
32.99
94.84
92.99
84.38
73.25
61.47
ROA
2.65%
4.38%
7.14%
4.37%
2.28%
1.02%
4.93%
7.02%
7.33%
1.95%
ROE
4.97%
7.86%
13.00%
8.65%
4.66%
2.17%
10.73%
15.07%
17.21%
5.29%
ROCE
8.29%
10.11%
16.82%
12.52%
8.70%
5.39%
14.64%
16.46%
14.20%
9.95%
Fixed Asset Turnover
1.40
1.58
2.10
1.93
1.89
1.88
2.70
2.60
2.21
2.43
Receivable days
99.71
97.06
84.61
88.55
83.26
105.81
99.21
118.05
133.84
112.03
Inventory Days
80.76
67.04
59.07
70.95
65.77
73.23
58.02
57.91
55.43
55.29
Payable days
143.40
128.40
127.86
166.10
150.56
175.89
88.19
86.92
85.73
87.08
Cash Conversion Cycle
37.07
35.70
15.82
-6.61
-1.53
3.15
69.04
89.04
103.54
80.25
Total Debt/Equity
0.45
0.44
0.30
0.29
0.50
0.59
0.52
0.60
0.68
0.98
Interest Cover
2.58
4.41
7.34
3.53
1.94
1.01
3.08
3.67
2.67
1.39

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • ZIM Laboratories secures marketing authorization for ‘Dabigatran Etexilate’ in Italy
    20th May 2026, 10:11 AM

    This authorisation will facilitate faster approvals in other European Union countries as well as the UK

    Read More
  • Zim Laboratories - Quarterly Results
    20th May 2026, 00:00 AM

    Read More
  • ZIM Laboratories invests Rs 89.45 lakh in ZIMTAS
    9th Apr 2026, 15:42 PM

    Post investment, the company holds 99.96% of the total share capital of ZIMTAS

    Read More
  • Zim Laboratories gets nod to incorporate subsidiary in Chile
    12th Feb 2026, 10:39 AM

    The incorporation of Wholly owned subsidiary is with an objective of expansion and development of business in the LATAM region

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.